Dr Reddy’s share price climbs 1.6%; Q1 FY26 revenue +11%

Stock moves higher in early trade

Dr Reddy’s Laboratories Ltd. was trading at ₹1,291.90 on Monday, June 22, 2026 (09:59:46), up 1.60% from its previous close of ₹1,271.55. The stock’s intraday range was ₹1,272.05 to ₹1,306.00 during the session referenced. The move came alongside a fresh focus on the company’s quarterly numbers and profitability trends that show sharp fluctuations across periods.

Separately cited trading data also pointed to a different snapshot where the stock was marked at ₹1,258.30 after falling 1.83% from ₹1,281.70, and exchange quotes on June 11, 2026 showed ₹1,275.05 on BSE and ₹1,277.70 on NSE. These data points reflect that the stock has been moving within a defined band in recent weeks, with the broader 52-week range cited at ₹1,149.00 to ₹1,377.95 (also cited as ₹1,148.40 to ₹1,375.90 in another market snapshot).

Recent performance: YTD flat, short-term weak

On the performance front, Dr Reddy’s was reported to be up 0.06% in the current year (year-to-date in the dataset) and down 0.26% over the last five trading days. The combination suggests a broadly range-bound trend for 2026 so far, with short-term pressure.

Daily trading levels were also captured with an open price of ₹1,267.00 and a previous close of ₹1,267.50 in one section of the data. While the exact reference points differ across the feeds included, the common takeaway is that the stock has remained within a relatively tight band around the ₹1,250 to ₹1,300 zone for portions of June.

Valuation snapshot and dividend yield

Dr Reddy’s was reported with a trailing twelve-month (TTM) P/E of 24.90, compared with a sector P/E of 28.23. Dividend yield was listed at 0.63% across the provided data. A final dividend recommendation of ₹8 per equity share (face value ₹1 each) for the year ended March 31, 2026 was also referenced.

EPS data in the feed was mixed, with EPS (TTM) listed at 49.81 in one section and 51.42 in another. These figures were presented as part of the same overall market snapshot context and are included as-is.

Q1 FY26 revenue rises, expenses also move up

The company’s consolidated sales for Q1 FY25-26 were reported at ₹8,572 crore, versus ₹7,696 crore in Q1 FY24-25. Expenses stood at ₹6,398 crore in Q1 FY25-26, compared with ₹5,566 crore in Q1 FY24-25. In another results summary, revenue was also presented as ₹85,452 million for Q1 FY26, which normalises to ₹8,545.2 crore, described as up 11% year-on-year.

EBITDA was reported at ₹22,784 million (₹2,278.4 crore) with a margin of 26.7% of revenues in the same summary. Taken together, these numbers point to revenue growth alongside higher costs, a key input for how investors interpret margin resilience.

Profit picture: sharp swings across quarters

Profitability figures in the provided data show sharp changes across different periods and definitions. One section stated the company posted a net profit of ₹220.90 crore in its last quarter, and another line described that net profit for Q4 2025-2026 fell 86.14% year-on-year to ₹220.90 crore. The same dataset said net profits fell 81.74% on a quarterly growth basis versus the prior three months.

At the same time, a quarterly table for “Quarter ended Jun 25” (with comparison columns for Mar 26 and Jun 24) listed Net Income at ₹1,418.10 crore for Jun 25 and ₹220.90 crore for Mar 26. The table also listed Total Revenue of ₹8,572.10 crore for Jun 25 versus ₹7,696.10 crore for Jun 24.

A separate line in the feed stated “Dr Reddy's Laboratories reported a net profit of 4196.00 Cr in 2026.” Since the dataset does not provide a reconciliation between this full-year figure and quarterly profit numbers, it is best read as an additional reported net profit figure for the year 2026 within the supplied source.

Analyst coverage and ratings

Coverage was reported from 38 analysts. Among them, 6 analysts had a strong buy rating and 12 had a buy rating, while 7 analysts rated the stock as sell. The feed did not provide counts for hold or other categories.

This level of coverage can influence how earnings prints and guidance updates get translated into investor narratives, particularly around margins, product launches, and geographic performance. However, the data provided here is limited to rating counts and does not include price targets.

Peer moves and sector context

Listed peers referenced alongside Dr Reddy’s included Lupin (down 0.30%), Torrent Pharmaceuticals (up 0.36%), and Divi’s Laboratories (up 0.52%) in the same snapshot. The sector comparison on valuation was also provided via the sector P/E of 28.23 versus Dr Reddy’s 24.90.

A separate business efficiency note in the data said the company spent less than 1% of operating revenues towards interest expenses and 17.09% towards employee cost in the year ending March 31, 2025 (consolidated financials). This offers additional context on cost structure, though it does not quantify absolute interest or employee expenses.

Key numbers at a glance

Q1 results table (as reported)

What investors will track next

The immediate marker on the calendar is the next earnings date reported as July 29, 2026. With revenue growth reported for Q1 FY26 and cost lines also rising, market focus typically stays on operating leverage and the stability of earnings across quarters.

For Dr Reddy’s, another area investors may track is how quarterly profitability behaves relative to the sharp decline reported for Q4 (net profit of ₹220.90 crore and an 86% year-on-year fall, as stated in the data). With differing profit figures presented across periods in the supplied feed, upcoming results and accompanying disclosures become an important checkpoint for clarity and comparability.